OKYO Pharma (OKYO Pharma) Change In Receivables : $0.17 Mil (TTM As of Mar. 2023)

View and export this data going back to 2022. Start your Free Trial

What is OKYO Pharma Change In Receivables?

OKYO Pharma's change in receivables for the quarter that ended in Mar. 2023 was $0.04 Mil. It means OKYO Pharma's Accounts Receivable declined by $0.04 Mil from Sep. 2022 to Mar. 2023 .

OKYO Pharma's change in receivables for the fiscal year that ended in Mar. 2023 was $0.17 Mil. It means OKYO Pharma's Accounts Receivable declined by $0.17 Mil from Mar. 2022 to Mar. 2023 .

OKYO Pharma's Accounts Receivable for the quarter that ended in Mar. 2023 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. OKYO Pharma's liquidation value for the six months ended in Mar. 2023 was $-3.21 Mil.

OKYO Pharma Change In Receivables Historical Data

The historical data trend for OKYO Pharma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OKYO Pharma Change In Receivables Chart

OKYO Pharma Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Change In Receivables

Get a 7-Day Free Trial

-0.13

-0.12

0.21

-0.78

0.17

OKYO Pharma Semi-Annual Data
	Sep13	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23
Change In Receivables	Get a 7-Day Free Trial															0.01	-0.08	-0.70	0.12	0.04

OKYO Pharma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.17 Mil.

OKYO Pharma (NAS:OKYO) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

OKYO Pharma's Days Sales Outstanding for the quarter that ended in Mar. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, OKYO Pharma's accounts receivable are only considered to be worth 75% of book value:

OKYO Pharma's liquidation value for the quarter that ended in Mar. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	4.045	-	7.257	+	0.75 * 0	+	0.5 * 0
=	-3.21

OKYO Pharma Change In Receivables Related Terms

Thank you for viewing the detailed overview of OKYO Pharma's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

OKYO Pharma (OKYO Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OKYO Pharma Ltd (NAS:OKYO) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

OK10:Germany

Address

14/15 Conduit St, Floor 4, London, GBR, W1S 2XJ

Website

https://www.okyopharma.com

OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions on various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.

Executives

John P Brancaccio	director	C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Gary S Jacob	director, officer: Chief Executive Officer
Gabriele M Cerrone	director, 10 percent owner, officer: Executive Chairman	265 EAST 66TH STREET, SUITE 16G, NEW YORK NY 10021
Bernard Denoyer	director	C/O CALLISTO PHARMACEUTICALS, INC., 420 LEXINGTON AVENUE, SUITE 1609, NEW YORK NY 10170
Willy Jules Simon	director	PLAYLOGIC INTERNATIONAL NV, CONCERTGEBOUWPLEIN 13, AMSTERDAM P7 1071 LL
Keeren Shah	officer: Chief Financial Officer	55 PARK LANE, LONDON X0 W1K 1NA